MalarVx, Inc., a clinical-stage vaccine company, is proud to announce a license to HDT Bio's proprietary self-amplifying ...
MalarVx, Inc., a clinical-stage vaccine company, is proud to announce a license to HDT Bio's proprietary self-amplifying replicon RNA (repRNA) and lipid nanoparticle (LIONtm) technologies for use in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback